// App-Quantinova.ai

PO1843 : Results of a Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers

Researchers

Presenter

  • Lo Jeannette

Principal Investigators

  • Yavrom Sharon

  • Fan Jessy

  • Endsley AaronN

  • Schroeder Tamara

  • Barratt Jonathan

  • Essayan DavidM

Medical Centers

  • Aduro BioTech Inc Berkeley California United States

  • Certara LP Princeton New Jersey United States

  • University of Leicester, Leicester, Leicestershire, United Kingdom

  • ONCORD Inc. Westlake Village California United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Nephrology

Disease

  • IgA nephropathy

Biomarkers

  • N/A

Drug/Treatment

  • BION-1301

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Pharmacodynamics

  • Double Blind/Blinded

  • Multiple Ascending Dose

  • Controlled

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved